Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients

This study highlights the requirement to investigate all patients with visible blood in the urine and an age threshold of ≥60 yr, as recommended in some guidelines, as the investigation of nonvisible blood in the urine will miss a significant number of urinary tract cancers. Patient preference is important, and evidence that patients are willing to submit to investigation should be considered in reaching a consensus recommendation for the investigation of haematuria. International consensus to guide that patients will benefit from investigation should be developed. Visible haematuria should be investigated regardless of age. While the risk of urinary tract cancer in patients with NVH, aged <60 yr, is low, clinically significant bladder cancers are still diagnosed. A Europe-wide consensus for haematuria should be developed.
Source: European Urology - Category: Urology & Nephrology Source Type: research